Abstract: Disclosed herein include antibodies or fragments thereof having specificity to a sarbecovirus spike protein. Also provided are compositions, methods, and kits for using said antibodies or fragments thereof for preventing or treating, for example a coronavirus infection.

Abstract: Disclosed herein include methods, compositions, and systems for designing antibody-small-molecule conjugates, for example antibody-drug conjugates (ADCs). The designed antibody-small-molecule conjugates can have, for example, higher binding affinities to the target protein compared to the small molecule alone or to a reference antibody-small-molecule conjugate (e.g., the parent antibody-small-molecule conjugate).

Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a.

Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a. A variant Cel5a endoglucanase is combined with variant Cel6a and variant Cel7a cellobiohydrolases resulting in more effective hydrolysis of cellulose.

Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a. A variant Cel5a endoglucanase is combined with variant Cel6a and variant Cel7a cellobiohydrolases resulting in more effective hydrolysis of cellulose.

Abstract: Engineered lectins and methods of using such reagents for both preventing and treating a broad array of viral infections are provided. The lectins of the invention are engineered in two ways, first through the enhancement of the natural mode of action of lectins against viruses through linked multimerization, and second through the creation of a new class of reagents, hereinafter referred to as a “lectibody” or “lectibodies”, that engage host immune function in addition to simply binding glycosylated viral proteins via the combination of a lectin and the Fc region of an antibody in order to drive Fc-mediated effector functions including ADCC (antibody-dependent cell-mediated cytotoxicity), increased half-life, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) in response to a lectin-mediated carbohydrate-binding event.

Abstract: A variant Cel5a endoglucanase has increased thermostability, increased enzymatic activity and/or increased expression in a host, relative to wild type Cel5a. The improved variant Cel5a endoglucanase may be used to hydrolyze more cellulose at a higher temperature for a more efficient and cost-effective production of biofuels as compared to wild type Cel5a.

Abstract: Engineered lectins and methods of using such reagents for both preventing and treating a broad array of viral infections are provided. The lectins of the invention are engineered in two ways, first through the enhancement of the natural mode of action of lectins against viruses through linked multimerization, and second through the creation of a new class of reagents, hereinafter referred to as a “lectibody” or “lectibodies”, that engage host immune function in addition to simply binding glycosylated viral proteins via the combination of a lectin and the Fc region of an antibody in order to drive Fc-mediated effector functions including ADCC (antibody-dependent cell-mediated cytotoxicity), increased half-life, complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADCP) in response to a lectin-mediated carbohydrate-binding event.

Abstract: The instant invention provides methods, reagents, and computational tools for designing non-natural substrate analogs for enzymes, especially for designing unnatural amino acid analogs for aminoacyl tRNA Synthetases (AARSs), such as the Phe tRNA Synthetase. The instant invention also provides methods to incorporate unnatural amino acid analogs, especially those with interesting functional groups, into protein products to generate proteins of modified or novel functions.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The instant invention provides methods, reagents, and computational tools for designing non-natural substrate analogs for enzymes, especially for designing unnatural amino acid analogs for aminoacyl tRNA Synthetases (AARSs), such as the Phe tRNA Synthetase. The instant invention also provides methods to incorporate unnatural amino acid analogs, especially those with interesting functional groups, into protein products to generate proteins of modified or novel functions.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The instant invention provides methods and computational tools for designing interaction between molecules based on their three-dimensional atomic coordinates. In a preferred embodiment, the method can be used to design protein-protein interactions based on their three-dimensional structure. In one embodiment, the method of the instant invention includes a first step of docking interacting molecules based on their surface geometric fit by quantitative correlation techniques, followed by a second step of optimizing the resulting interacting surface by altering interface side-chains, such that the interfacial side-chains are repacked in a manner analogous to the cores of well-folded proteins.

Abstract: The invention relates to improved methods for directed evolution of polymers, including directed evolution of nucleic acids and proteins. Specifically, the methods of the invention include analytical methods for identifying “crossover locations” in a polymer. Crossovers at these locations are less likely to disrupt desirable properties of the protein, such as stability or functionality. The invention further provides improved methods for directed evolution wherein the polymer is selectively recombined at the identified “crossover locations”. Crossover disruption profiles can be used to identify preferred crossover locations. Structural domains of a biopolymer can also be identified and analyzed, and domains can be organized into schema. Schema disruption profiles can be calculated, for example based on conformational energy or interatomic distances, and these can be used to identify preferred or candidate crossover locations.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.

Abstract: The invention relates to improved methods for directed evolution of polymers, including directed evolution of nucleic acids and proteins. Specifically, the methods of the invention include analytical methods for identifying “crossover locations” in a polymer. Crossovers at these locations are less likely to disrupt desirable properties of the protein, such as stability or functionality. The invention further provides improved methods for directed evolution wherein the polymer is selectively recombined at the identified “crossover locations”. Crossover disruption profiles can be used to identify preferred crossover locations. Structural domains of a biopolymer can also be identified and analyzed, and domains can be organized into schema. Schema disruption profiles can be calculated, for example based on conformational energy or interatomic distances, and these can be used to identify preferred or candidate crossover locations.

Abstract: The present invention relates to apparatus and methods for quantitative protein design and optimization.